Agile full service CRO, 16 years of expertise in clinical trials.

Connecting the dots !

EXPERTISE ATU /RTU (compassionate use)-Economic modelling-Real life studies

 

Managing your epidemiological and health economics studies


Statistical methology, health economics, market access

Immunotherapeutics, medical devices, rare diseases

Fostering your oncology phase II development in US & EU.

Clinical trials, epidemiology, US operations with strategic partner

FDA CDISC & ICH GCP compliant, R&D taxes reduction

News

Phagoburn
10/04/13 - Statitec selected to conduct PhagoBurn clinical trial

STATITEC the...

What is the “wake up juice” for biotech capitalization?
05/23/13 - What is the “wake up juice” for biotech capitalization?

As current global growth is difficult to capture, countries are trying to focus on...

Myeloma Phase III study  published in NEJM
07/02/12 - NEJM Myeloma Phase III publication

 

May 2012 New England Journal of Medicine published results from a phase...

Gearing up Life sciences innovation
03/16/12 - Gearing up life sciences innovation to today's economic twist

This Statitec perspective paper is aiming at...

Vidéo

Video Presentation

Key assets of Statitec :

  • Taxes reduction accreditation for R&D
  • Expertise in rare malignancies & ATU
  • Experience in FDA submission

Twitter